Comparing Ticagrelor Alone Versus Aspirin and Clopidogrel After PCI in Chronic Coronary Syndrome Patients A 6-Month Randomized Study at a Single Center

What this Trial Is About

Researchers are evaluating the safety and effectiveness of two antiplatelet treatments for patients with chronic coronary syndrome who undergo percutaneous coronary intervention PCI using drug-eluting stents. The trial compares ticagrelor alone against the standard dual therapy of aspirin and clopidogrel. The study aims to measure major adverse cardiovascular events MACE, including cardiac death, myocardial infarction, stent thrombosis, and the need for further revascularization within six months after PCI. Patients will be randomly assigned to one of two groups after diagnostic angiography but before stent placement. One group will receive conventional dual antiplatelet therapy consisting of aspirin 80 mg once daily and clopidogrel 75 mg once daily. The other group will receive ticagrelor monotherapy at 90 mg twice daily. Treatment will begin with a loading dose before stent insertion unless patients are already on maintenance therapy. The intervention period lasts for six months. Participants will be monitored throughout the study for cardiovascular events, bleeding, and adverse treatment reactions. The study includes detailed safety assessments, and outcomes such as stent thrombosis and MACE will be tracked for six months post-PCI. The trial uses a randomized, triple-blind design and involves follow-up within a registry at a cardiology clinic. The total participation time covers the initial procedure and six months of treatment and monitoring.

Ticagrelore Alone Post PCI